Colossal raises $150M Series B

Colossal Biosciences

Colossal raised a $150M Series B led by United States Innovative Technology Fund, valuing it at >$1B and bringing total funding to $225M since its 2021 launch. It added the dodo to its de-extinction targets alongside the woolly mammoth and Tasmanian tiger, and set up an avian genomics group.

• Series B valuation >$1B; funding now $225M (vs $75M after Series A in March 2022).
• Investors: UITF, Breyer Capital, WestRiver, Animal Capital, Animoca, Peak 6, Bold Capital, Jazz Ventures.
• New avian division focuses on dodo restoration; combines mammal (mammoth, tiger) and bird targets.
• De-extinction combines CRISPR, ancient-DNA recovery and artificial-reproduction technologies.